Phase II trial for intraperitoneal cisplatin plus intravenous sodium thiosulphate in advanced ovarian carcinoma patients with minimal residual disease after cisplatin-based chemotherapy--a phase II study of the EORTC Gynaecological Cancer Cooperative Group.

[1]  M. Piver,et al.  Surgically documented response to intraperitoneal cisplatin, cytarabine, and bleomycin after intravenous cisplatin-based chemotherapy in advanced ovarian adenocarcinoma. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Howell Sb.  Intraperitoneal chemotherapy: the use of concurrent systemic neutralizing agents. , 1985 .

[3]  Dedrick Rl.  Theoretical and experimental bases of intraperitoneal chemotherapy. , 1985 .

[4]  D. Alberts,et al.  Intraperitoneal chemotherapy: technical experience at five institutions. , 1985, Seminars in oncology.

[5]  Morgan Lr.  Megestrol acetate v tamoxifen in advanced breast cancer in postmenopausal patients. , 1985 .

[6]  J. Neijt,et al.  RANDOMISED TRIAL COMPARING TWO COMBINATION CHEMOTHERAPY REGIMENS (HEXA-CAF VS CHAP-5) IN ADVANCED OVARIAN CARCINOMA , 1984, The Lancet.

[7]  N. Hacker,et al.  Pharmacokinetics of Ip cisplatin in refractory ovarian carcinoma. , 1983, Cancer treatment reports.

[8]  R. Olshen,et al.  Intraperitoneal cis-diamminedichloroplatinum with systemic thiosulfate protection. , 1983, Cancer research.

[9]  R. Olshen,et al.  Intraperitoneal cisplatin with systemic thiosulfate protection. , 1982, Annals of internal medicine.

[10]  P. Sugarbaker,et al.  Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans. , 1981, Cancer research.

[11]  V. Devita,et al.  High-volume intraperitoneal chemotherapy with methotrexate in patients with cancer. , 1981, Cancer research.